UNITED GUARDIAN INC - 10-K Filing Summary
Business Context and Reporting Period
Company: United-Guardian, Inc. (UG)
Filing Type: Annual Report on Form 10-K
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: The Company manufactures and markets specialty cosmetic ingredients, pharmaceutical products, medical lubricants, and sexual wellness ingredients. It operates as a single business segment. In 2023, the Company discontinued its industrial product line due to low volume. In October 2023, it entered a distribution agreement with Brenntag Specialties for its new Natrajel sexual wellness line, with sales expected to begin in 2025.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Net Sales | $12,181,971 | $10,885,154 |
| Gross Profit Margin | 53.0% | 50.0% |
| Operating Income | $3,646,789 | $2,863,032 |
| Net Income | $3,250,875 | $2,581,370 |
| Earnings Per Share (Basic/Diluted) | $0.71 | $0.56 |
| Cash from Operations | $3,466,251 | $3,144,480 |
| Working Capital | $10,751,082 | $10,718,457 |
| Current Ratio | 6.6 to 1 | 8.0 to 1 |
| Total Assets | $13,797,335 | $12,922,838 |
| Total Liabilities | $1,914,469 | $1,534,256 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 12% to $12.18 million, driven primarily by a 32% increase in cosmetic ingredient sales (specifically a 51% increase to largest distributor ASI) and a 16% increase in medical lubricant sales.
- Pharmaceutical Decline: Net pharmaceutical sales decreased 5% due to a temporary manufacturing halt of the Renacidin product line in late 2023/early 2024 and reduced government rebates.
- Margin Expansion: Gross profit margin improved from 50% to 53%, attributed to a higher mix of high-margin cosmetic sales and lower per-unit overhead costs due to increased production volume.
- Investment Strategy Shift: The Company repositioned its portfolio from short-term cash equivalents to longer-term marketable securities (U.S. Treasury Bills and CDs) to capture higher interest rates, resulting in a 42% increase in investment income.
- Dividend Increase: Total dividends paid increased significantly to $2.76 million ($0.60 per share) in 2024 compared to $0.46 million ($0.10 per share) in 2023.
Guidance, Outlook, Risks, and Contingencies
- New Product Launch: The Company anticipates beginning manufacturing and reporting sales of the Natrajel sexual wellness line in 2025. No sales were recorded in 2024.
- Regulatory Impact (Medicare): A new Medicare Part D Manufacturer Discount Program implemented in January 2025 is expected to increase rebate liabilities over time. However, the Company qualified as a "specified small manufacturer," granting a multi-year phase-in period with reduced rebates through 2026, with full liability expected by 2031.
- Supply Chain & Tariffs: The Company monitors Red Sea/Suez Canal disruptions and new tariffs imposed by the Trump administration on imports from China, Canada, and Mexico. While raw material exposure is currently limited, potential tariffs on finished goods manufactured in China could impact demand.
- Distributor Renegotiation: The exclusive distribution agreement with Ashland Specialty Ingredients (ASI) terminated on December 31, 2023. The Company is renegotiating terms, with a new agreement hoped for by mid-2025. Operations continue under existing practices during negotiations.
- Capital Expenditures: The Company incurred approximately $181,000 for a sprinkler system upgrade and $237,000 for a roof replacement in 2024. Additional expenditures of $14,000 are planned for Q1 2025.
Investor Verification Checklist
- ASI Contract Status: Verify the status of the renegotiation with Ashland Specialty Ingredients (ASI), which accounts for approximately 41% of total sales, to ensure continuity of the largest revenue stream.
- Medicare Rebate Liability: Review the specific financial modeling regarding the new Medicare Part D Discount Program to understand the long-term impact on net sales and margins post-2026.
- Renacidin Production: Confirm that the contract manufacturer for Renacidin has fully stabilized production and that no further supply disruptions are anticipated.
- Tariff Exposure: Assess the potential indirect impact of tariffs on finished goods manufactured in China that utilize the Company's ingredients, which could reduce downstream demand.
- Investment Liquidity: Evaluate the liquidity profile of the $7.5 million in marketable securities, noting the shift to longer-term maturities, to ensure sufficient cash flow for operations and dividends.